Select a medication above to begin.
Bizengri (zenocutuzumab-zbco)
zenocutuzumab
Black Box Warnings .
Embryo-Fetal Toxicity
exposure during pregnancy or w/in 2mo prior to conception can result in embryo-fetal harm, incl. oligohydramnios; advise pts of risks and need for effective contraception
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = zenocutuzumab-zbco
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
NRG1 fusion-positive non-small cell lung CA, advanced unresectable or metastatic
- [750 mg IV q2wk]
- Info: for pts w/ progressive dz
NRG1 fusion-positive pancreatic CA, advanced unresectable or metastatic
- [750 mg IV q2wk]
- Info: for pts w/ progressive dz
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.